Current Heart Failure Reports

, Volume 6, Issue 4, pp 220–228

β-Adrenergic receptor blockers and heart failure risk after myocardial infarction: A critical review

Article

Abstract

Remodeling after myocardial infarction is a complex biological process that leads to progressive left ventricular dilation and clinical heart failure. Multiple influences, including autonomic imbalance with sympathetic activation, contribute to the process. This article reviews clinical data in favor of early- and long-term use of β-adrenergic receptor blockers in patients after myocardial infarction. Areas of uncertainty, such as the selection of dose and duration of therapy, current guidelines, and patterns of underuse of therapy with this important class of drugs are outlined and highlighted.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart Disease and Stroke Statistics—2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21–e181.CrossRefPubMedGoogle Scholar
  2. 2.
    Køer L, Torp-Pedersen C, Jørgensen S, et al.: Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. Am J Cardiol 1998, 81:1292–1297.CrossRefGoogle Scholar
  3. 3.
    Giannuzzi P, Temporelli PL, Bosimini E, et al.: Heterogeneity of left ventricular remodeling after acute myocardial infarction. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-3 Echo Substudy. Am Heart J 2001, 141:131–138.CrossRefPubMedGoogle Scholar
  4. 4.
    Gaudron P, Eilles C, Kugler I, Ertl G: Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993, 87:755–763.PubMedGoogle Scholar
  5. 5.
    Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327:669–677.PubMedGoogle Scholar
  6. 6.
    Lanza GA, Guido V, Galeazzi MM, et al.: Prognostic role of heart rate variability in patients with a recent acute myocardial infarction. Am J Cardiol 1998, 82:1323–1328.CrossRefPubMedGoogle Scholar
  7. 7.
    Migrino RQ, Young JB, Ellis SG, et al.: End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. Circulation 1997, 96:116–121.PubMedGoogle Scholar
  8. 8.
    Wu AH, Parsons L, Every NR, et al.: Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002, 40:1389–1394.CrossRefPubMedGoogle Scholar
  9. 9.
    Hasdai D, Topol EJ, Kilaru R, et al.: Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 2003, 145:73–79.CrossRefPubMedGoogle Scholar
  10. 10.
    Steg PG, Dabbous OH, Feldman LJ, et al.: Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004, 109:494–499.CrossRefPubMedGoogle Scholar
  11. 11.
    Cohn JN, Johnson GR, Shabetai R, et al.: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87:VI5–VI16.PubMedGoogle Scholar
  12. 12.
    Wang T, Levy D, Benjamin E, Vasan R: The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003, 138:907–916.PubMedGoogle Scholar
  13. 13.
    McDonagh TA, Morrison CE, Lawrence A, et al.: Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997, 350:829–833.CrossRefPubMedGoogle Scholar
  14. 14.
    St John Sutton M, Pfeffer MA, Plappert T, et al.: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994, 89:68–75.PubMedGoogle Scholar
  15. 15.
    Konstam MA, Rousseau MF, Kronenberg MW, et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992, 86:431–438.PubMedGoogle Scholar
  16. 16.
    Greenberg B, Quinones MA, Koilpillai C, et al.: Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995, 91:2573–2581.PubMedGoogle Scholar
  17. 17.
    Pfeffer MA, Lamas GA, Vaughan DE, et al.: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988, 319:80–86.PubMedGoogle Scholar
  18. 18.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial Infarction complicated by heart Failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.CrossRefPubMedGoogle Scholar
  19. 19.
    Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.CrossRefPubMedGoogle Scholar
  20. 20.
    Bristow MR: Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558–569.PubMedGoogle Scholar
  21. 21.
    Mann DL: Stress activated cytokines and the heart. Cytokine Growth Factor Rev 1996, 7:341–354.CrossRefPubMedGoogle Scholar
  22. 22.
    Spyrou N, Rosen SD, Fath-Ordoubadi F, et al.: Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol 2000, 36:2072–2080.CrossRefGoogle Scholar
  23. 23.
    Lopez-Sendon J, Swedberg K, McMurray J, et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004, 25:1341–1362.CrossRefPubMedGoogle Scholar
  24. 24.
    Ryden L, Ariniego R, Arnman K, et al.: A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983, 308:614–618.PubMedCrossRefGoogle Scholar
  25. 25.
    Lowes BD, Gill EA, Abraham WT, et al.: Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol 1999, 83:1201–1205.CrossRefPubMedGoogle Scholar
  26. 26.
    Hall SA, Cigarroa CG, Marcoux L, et al.: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995, 25:1154–1161.CrossRefPubMedGoogle Scholar
  27. 27.
    Poulsen SH, Jensen SE, Egstrup K: Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. Am Heart J 1999, 138:710–720.CrossRefPubMedGoogle Scholar
  28. 28.
    Yusuf S, Peto R, Lewis J, et al.: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335–371.CrossRefPubMedGoogle Scholar
  29. 29.
    First International Study of Infarct Survival Collaborative Group: Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. Lancet 1988, 1:921–923.Google Scholar
  30. 30.
    First International Study of Infarct Survival Collaborative Group: Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986, 2:57–66.Google Scholar
  31. 31.
    MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985, 6:199–226.Google Scholar
  32. 32.
    Hjalmarson A, Herlitz, J Holmberg S, et al.: The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983, 67:I26–I32.PubMedGoogle Scholar
  33. 33.
    Roberts R, Rogers WJ, Mueller HS, et al.: Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation 1991, 83:422–437.PubMedGoogle Scholar
  34. 34.
    Van de Werf F, Janssens L, Brzostek T, et al.: Short-term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993, 22:407–416.PubMedCrossRefGoogle Scholar
  35. 35.
    Pfisterer M, Cox JL, Granger CB, et al.: Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998, 32:634–640.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen ZM, Pan HC, Chen YP, et al.: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1622–1632.CrossRefPubMedGoogle Scholar
  37. 37.
    Halkin A, Grines CL, Cox DA, et al.: Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004, 43:1780–1787.CrossRefPubMedGoogle Scholar
  38. 38.
    Kernis SJ, Harjai KJ, Stone GW, et al.: Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004, 43:1773–1779.CrossRefPubMedGoogle Scholar
  39. 39.
    Freemantle N, Cleland J, Young P, et al.: Beta blockade after myocardial infarction: systematic review and metaregression analysis. BMJ 1999, 318:1730–1737.PubMedGoogle Scholar
  40. 40.
    Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981, 304:801–807.CrossRefGoogle Scholar
  41. 41.
    Beta-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982, 247:1707–1714.CrossRefGoogle Scholar
  42. 42.
    Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986, 73:503–510.PubMedGoogle Scholar
  43. 43.
    Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385–1390.CrossRefPubMedGoogle Scholar
  44. 44.
    Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998, 339:489–497.CrossRefPubMedGoogle Scholar
  45. 45.
    Dahlöf B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895–906.CrossRefPubMedGoogle Scholar
  46. 46.
    Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: is it a wise choice? Lancet 2004, 364:1684–1689.CrossRefPubMedGoogle Scholar
  47. 47.
    Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): a randomised controlled trial. Lancet 2003, 362:7–13.CrossRefPubMedGoogle Scholar
  48. 48.
    Mrdovic IB, Savic LZ, Perunicic JP, et al.: Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 2007, 154:116–122.CrossRefPubMedGoogle Scholar
  49. 49.
    Pilote L, Abrahamowicz M, Eisenberg M, et al.: Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008, 178:1303–1311.PubMedGoogle Scholar
  50. 50.
    Kjekshus JK: Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986, 57:43F–49F.CrossRefPubMedGoogle Scholar
  51. 51.
    Cucherat M: Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007, 28:3012–3019.CrossRefPubMedGoogle Scholar
  52. 52.
    Ko DT, Hebert PR, Coffey CS, et al.: Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002, 288:351–357.CrossRefPubMedGoogle Scholar
  53. 53.
    Byington RP, Worthy J, Craven T, et al.: Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the beta-blocker Heart Attack Trial experience. Am J Cardiol 1990, 65:1287–1291.CrossRefPubMedGoogle Scholar
  54. 54.
    Fonarow GC, Abraham WT, Albert NM, et al.: Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007, 167:1493–1502.CrossRefPubMedGoogle Scholar
  55. 55.
    Kennedy HL, Brooks MM, Barker AH, et al.: Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 1994, 74:674–680.CrossRefPubMedGoogle Scholar
  56. 56.
    Pedersen TR: Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med 1985, 313:1055–1058.PubMedCrossRefGoogle Scholar
  57. 57.
    Olsson G, Oden A, Johansson L, et al.: Prognosis after withdrawal of chronic post-infarction metoprolol treatment. A 2 to 7 year follow-up. Eur Heart J 1988, 9:365–372.PubMedGoogle Scholar
  58. 58.
    Viscoli CM, Horwitz RI, Singer BH: Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 1993, 118:99–105.PubMedGoogle Scholar
  59. 59.
    Krumholz HM, Radford MJ, Wang Y, et al.: National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998, 280:623–629.CrossRefPubMedGoogle Scholar
  60. 60.
    Hasdai D, Behar S, Wallentin L, et al.: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002, 23:1190–1201.CrossRefPubMedGoogle Scholar
  61. 61.
    Steg P, Goldberg R, Gore J, et al.: Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002, 90:358–363.CrossRefPubMedGoogle Scholar
  62. 62.
    Butler J, Arbogast PG, BeLue R, et al.: Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002, 40:1589–1595.CrossRefPubMedGoogle Scholar
  63. 63.
    Gislason GH, Rasmussen JN, Abildstrom SZ, et al.: Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006, 27:1153–1158.CrossRefPubMedGoogle Scholar
  64. 64.
    Hauptman PJ: Medication adherence in heart failure. Heart Fail Rev 2008, 13:99–106.CrossRefPubMedGoogle Scholar
  65. 65.
    Antman EM, Anbe DT, Armstrong PW: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2004, 110:e82–e293.CrossRefPubMedGoogle Scholar
  66. 66.
    Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al.: 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol 2008, 51:210–247.CrossRefGoogle Scholar
  67. 67.
    Anderson JL, Adams CD, Antman EM, et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007, 50:e1–e157.CrossRefPubMedGoogle Scholar
  68. 68.
    Seow H, Phillips C, Rich MW, et al.: Isolation of health services research from practice and policy: the examples of chronic heart failure management. J Am Geriatr Soc 2006, 54:535–540.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Cardiology, FDT-15Saint Louis University HospitalSaint LouisUSA

Personalised recommendations